Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PLG | P00747 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | C1S | P09871 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638088 | 0.79 | PARP1 (0.48) | BLMRECQLKMT2A | |
| SCHEMBL6022934 | 0.77 | F12 (0.44) | LMNAPRSS1PRSS2PRSS3F2 | |
| SCHEMBL7975105 | 0.76 | — | — | |
| SCHEMBL1950632 | 0.75 | PRSS1 (0.50) | LMNAPRSS1PRSS2PRSS3F2 | |
| SCHEMBL1949948 | 0.75 | PRSS1 (0.41) | LMNAPRSS1PRSS2PRSS3F2 | |
| SCHEMBL7992402 | 0.75 | — | — | |
| SCHEMBL8169108 | 0.74 | LMNA (0.48) | LMNAPRSS1PRSS2PRSS3PLAU | |
| SCHEMBL1205901 | 0.72 | TSHR (0.48) | — | |
| SCHEMBL8162967 | 0.72 | PRSS1 (0.39) | LMNAPRSS1PRSS2PRSS3F2 | |
| SCHEMBL9030801 | 0.71 | PRSS1 (0.44) | LMNAPRSS1PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2373634-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | Mochida Pharmaceutical Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5302390-A | ADMINISTERING TO TREAT THROMBOTIC DISEASES | BEECHAM GROUP PLC (GB) | 1994-04-12 | — | — | US | disclosed |
| EP-0297882-B1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1993-08-25 | — | — | EP | disclosed |
| EP-0370711-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-05-30 | — | — | EP | disclosed |
| EP-0297882-A2 | Hybrid plasminogen activators | BEECHAM GROUP PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | LMNA 95/4885PRSS1 405/4885PRSS2 1421/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | LMNA 95/4885PRSS1 405/4885PRSS2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.